BioSpace News Archive

The biopharma’s acute myeloid leukemia hopeful is on partial clinical hold, affecting two Phase III AML studies, Gilead announced Monday. The CD47 candidate also spent four months on hold in 2022.

Many products are facing the loss of their patents or exclusivity clauses. Here’s what to expect in the coming months.

BioSpace’s annual Salary Report explores the average salaries and salary trends of life sciences professionals.

Eilean Therapeutics LLC today announced the initiation of human dosing in the Phase 1 clinical program of ZE46-0134, a highly potent and selective pan-FLT3 inhibitor that targets clinically relevant FLT3 mutations including the FLT3 gatekeeper mutation, while sparing the wild type form of the protein.

Adial Pharmaceuticals, Inc. today provided a business update and reported its financial results for the second quarter of 2023.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia (AML).

IRLAB Therapeutics, a company discovering and developing novel treatments for Parkinson’s disease, announced the transfer of rights for the now Phase III-ready mesdopetam project to IRLAB.

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson’s disease, today announced further information on the results from mesdopetam’s clinical Phase IIb study in Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs) and Phase III preparatory Phase I studies performed by Ipsen.

Integra Connect, LLC. announced today that JCO Oncology Practice, an American Society of Clinical Oncology Journal, published a study that found initiating treatment prior to receiving genomic test results for actionable oncogenic drivers (AODs) in advanced non-small-cell lung cancer (NSCLC) leads to considerably inferior patient outcomes.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that Bethany L. Sensenig has joined the Supernus Board of Directors effective immediately.